FOXO Technologies Exclusively Licenses Epigenetic Clocks PhenoAge and GrimAge from UCLA
News provided by
Share this article
Share this article
MINNEAPOLIS, May 5, 2021 /PRNewswire/ FOXO Technologies Inc. ( FOXO ) today announced the license of two epigenetic clocks, PhenoAge and GrimAge, for use in the prediction of human mortality in the life insurance industry. These licenses, in addition to the Epigenetic Mortality Predictor, give FOXO the exclusive usage of epigenetic clocks developed by Dr. Steve Horvath for the financial services industry.
FOXO uses artificial intelligence, epigenetics, and cutting-edge bioinformatics tools to develop and commercialize epigenetic biomarkers of health and aging. FOXO sees broad application for its proprietary biomarker technology for insurers, health researchers, and life science companies. Securing the additional licenses give FOXO a competitive advantage in its mission to modernize life insurance through FOXO LIFE. FOXO LIFE seeks to r